Results 171 to 180 of about 10,200,147 (283)

Anti–Carbamylated Fibrinogen Autoantibodies of IgG and IgA Isotypes Contribute to a Better Prognostic Stratification in Very Early Rheumatoid Arthritis: Data From the French National ESPOIR Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate the prevalence and longitudinal evolution of anti–carbamylated fibrinogen antibodies (ACa‐Fib) of IgG and IgA isotypes in early rheumatoid arthritis (RA) and determine whether these antibodies provide additional diagnostic and prognostic information beyond anti–cyclic citrullinated peptide (anti‐CCP ...
Pauline Brevet   +11 more
wiley   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych   +10 more
wiley   +1 more source

The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Plasma calprotectin is a marker of neutrophil activity. Its relation to the clinical phenotype and autoantibodies in rheumatoid arthritis (RA) is only partly understood. We therefore aimed to investigate the association between calprotectin and clinical parameters, CRP, ESR, anti‐CCP2 and other anti‐modified protein autoantibodies (AMPAs) in
Caroline Grönwall   +34 more
wiley   +1 more source

Long‐Term Risk of Rheumatoid Arthritis in Individuals With Autism Spectrum Disorder: A Population‐Based Matched Cohort Study

open access: yesAutism Research, EarlyView.
ABSTRACT To investigate the long‐term risk of rheumatoid arthritis (RA) among individuals with autism spectrum disorder (ASD), addressing potential immune comorbidity in ASD populations. A population‐based matched cohort was assembled using Swedish registers, including 46,164 individuals diagnosed with ASD between 1987 and 2017, matched to 4,634,895 ...
Evora Hailin Zhu   +10 more
wiley   +1 more source

Emotion Regulation Difficulties in Autism‐PTSD Co‐Occurrence

open access: yesAutism Research, EarlyView.
ABSTRACT Autistic individuals face an increased risk of experiencing traumatic events and of being significantly affected by them, whether these events are life‐threatening or social in nature. Emotion regulation (ER) difficulties are central to both conditions, yet their role in this neuropsychiatric co‐occurrence remains under‐researched.
Eldar Fayena   +6 more
wiley   +1 more source

Biobased Sunflower Stalk Matrix for Lipase Stabilization via Physical Adsorption

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT The search for sustainable, cost‐effective biocatalytic processes has driven efforts to develop low‐cost supports for enzyme immobilization. Lignocellulosic residues have received particular attention due to their abundance, renewability, and structural properties.
Jaci L. Vilanova Neta   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy